Negocios · 31/10/20031 min de lectura
Implantation or Injectable Dosage Form New Animal Drugs; Sometribove Zinc Suspension
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Monsanto Co. The supplemental NADA provides for revised wording of the indication and precautionary labeling for sometribove zinc suspension used to increase the production of marketable milk in healthy lactating dairy cows. The regulations are also being amended to reflect a different drug labeler code (DLC) for Monsanto Co.